August 08, 2018 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Liabilities of $157,473,000 USD. Previously, on May 10, 2018, La Jolla Pharmaceutical Co. reported Liabilities of $29,488,000 USD. This represents a change of 434.02% in Liabilities.

Period EndPeriodValue
2018-06-30 2018-Q2 157,473,000
2018-03-31 2018-Q1 29,488,000
2017-12-31 2017-Q4 31,337,000
2016-12-31 2016-Q4 9,758,000
AllocatedShareBasedCompensationExpense CostsAndExpenses GeneralAndAdministrativeExpense IncomeTaxExaminationPenaltiesAndInterestExpense IncomeTaxExpenseBenefit IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets LeaseAndRentalExpense OtherNonoperatingIncomeExpense PrepaidExpenseAndOtherAssetsCurrent ResearchAndDevelopmentExpense RevenueFromRelatedParties Revenues WarrantGrantstoThirdPartiesCompensationExpense

Related News Stories

Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-9)

7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

CUSIP: 503459604